Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). The Lancet peer review validates HOPE-3 methodology, but revised LVEF result weakened to p=0.09 from p=0.04.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- The Lancet peer review validates HOPE-3 methodology, but revised LVEF result weakened to p=0.09 from p=0.04
- LVEF treatment difference narrowed to 1.8 percentage points from 2.4 percentage points
- Cardiomyopathy subgroup remained nominally significant at p=0.02 with 2.8 percentage point treatment difference
- Primary efficacy endpoint and other trial data unchanged, preserving the core BLA evidence package
- FDA BIMO inspection identified one observation involving procedures, documentation, vendor oversight, and audit timeliness
Item EX-99.1 · Exhibit EX-99.1
- The Lancet publication independently validates HOPE-3’s design, statistical methodology, and findings ahead of FDA action
- Phase 3 HOPE-3 trial enrolled 106 patients and met its primary endpoint
- Deramiocel slowed upper-limb functional decline 54% versus placebo, with PUL 2.0 significance of p=0.03
- Clinically meaningful cardiac benefits strengthen the therapy’s potential value in Duchenne muscular dystrophy
- FDA BLA review remains active, with PDUFA target action date August 22, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.